Trial intelligence / Profile preview

Pegasys + Copegus retreatment for relapsed chronic hepatitis C genotype 2 or 3

2006-003409-18Phase 3Completed

Sponsor
Sahlgrenska University Hospital
Start
Sep 2006
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, open-label trial of interferon alfa and ribavirin in hepatitis C virus infection (2 arms), sponsored by Sahlgrenska University Hospital. Primary endpoint: Sustained virologic response rate. Started Sep 2006; status: completed.

02

Drugs

interferon alfaribavirin
03

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2006-003409-18.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-003409-18.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call